Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Evaxion presents new data for off-the-shelf AML vaccine

Evaxion (NASDAQ: EVAX) has announced new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML) that targets multiple endogenous retrovirus (ERV) tumor antigens...

June 11, 2026

Developments

60 Degrees signs licensing agreement with Florida State for botanical supplement

60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) has announced that it has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify...

June 11, 2026

Developments

Caribou reports long-term vispa-cel data in r/r B-NHL

Caribou Biosciences (NASDAQ: CRBU) has announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial for...

June 11, 2026

Developments

Valion confirms HASC initiative to address urgent need for radiation/nuclear countermeasures

Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee‘s FY27 National Defense Authorization Act report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and...

June 11, 2026

Markets

Rodman & Renshaw starts Kyntra Bio at buy; PT $30

Rodman & Renshaw initiated coverage of Kyntra Bio (NASDAQ: KYNB) with a “buy” rating and price target of $30.00. The stock closed at $6.63 on June 8. Kyntra Bio (formerly known as FibroGen) is a biopharmaceutical...

June 10, 2026

Developments

Cantargia reports launch of investigator-led lung cancer prevention study

Cantargia (STO: CANTA) has announced that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and at...

June 10, 2026

Developments

Sensorion selects SENS-601 for hearing loss as lead program; files for trials in Canada and France

Sensorion (EPA: ALSEN) announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A clinical trial application has been filed in Canada and France to evaluate the safety...

June 10, 2026

Developments

Cullinan shares data from T cell engager programs targeting autoimmune diseases

Cullinan Therapeutics (NASDAQ: CGEM) has reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, in autoimmune diseases...

June 10, 2026

Developments

INOVATE selects Perimeter for contribution to advance AI for breast cancer surgery

Perimeter Medical Imaging (TSXV: PINK; OTCQX: PYNKF) has announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product Claire...

June 9, 2026

Developments

FDA clears Pentixapharm IND for cardiovascular diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) has announced that the FDA has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant...

June 9, 2026

Developments

ZEO adds nine experts in regenerative and longevity medicine to advisory board

ZEO ScientifiX (OTCQB: ZEOX) has announced the expansion of its medical advisory board with the addition of nine physicians and scientific innovators across key disciplines in regenerative and longevity medicine. The...

June 9, 2026

Developments

Eledon reports insulin independence in islet transplant patients treated with tegoprubart

Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free...

June 8, 2026

Subscribe